Cabozantinib Active in Advanced Thyroid Cancer (CME/CE)

11:45 EST 13 Feb 2018 | MedPageToday

Related Biotechnology, Pharmaceutical and Healthcare News

(MedPage Today) -- Responses in 19 of 35 patients with RAI-refractory disease

Original Article: Cabozantinib Active in Advanced Thyroid Cancer (CME/CE)

NEXT ARTICLE

More From BioPortfolio on "Cabozantinib Active in Advanced Thyroid Cancer (CME/CE)"